fbpx
Connect with us

Hi, what are you looking for?

UpNow Media

Finance

Novavax coronavirus vaccine promising to achieve 100m doses by the end of 2020

Novavax coronavirus vaccines are estimated to be ready by end of 2020. 100m doses are expected to be produced according to Gregory Glenn, the R&D Chief of the company.

Novavax Belward Campus

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

U.S. biotech company Novavax is “confident” in its ability to scale up to 100 million doses of a coronavirus vaccine by the end of the year after starting Phase 1 trials on a vaccine candidate on Monday, Novavax president of research and development Gregory Glenn said on Tuesday.

“I’m very optimistic with our data that we can come out with a vaccine that’s deployable, that could work,” Glenn said. “We think we could make 100 million doses by the end of the year for use.”

Novavax coronavirus vaccine tests

Novavax coronavirus vaccines are starting phase 1 trials.
Takara Bio, Moderna & Novavax are in the running to create coronavirus vaccines.

“We normally wait. Confirm it’s working, and then you scale it up. We’re not waiting. We’ve begun to scale up to make a vaccine that can be deployed,” Glenn said.

If its vaccine candidate works, Novavax could scale up to 1.5 billion doses “at least” in 2021, in part thanks to $388 million from the Coalition for Epidemic Preparedness and Innovation, Glenn said.

Maryland-based Novavax just began dosing for the Phase 1 clinical trial in Australia. If Phase 1 is successful, Novavax will follow up with Phase 2 in multiple countries including the U.S. using participants in a broader age range.

“Vaccines are really miracles. They change lives,” Glenn said. “People could walk out the door knowing they’re protected. That would be a complete change in the environment we’re in.”

https://upnowmedia.com/takara-bio-coronavirus-vaccine-scale-up-cytiva

Other companies with potential vaccines

Another U.S. biotech company, Massachusetts-based Moderna, has already started a Phase 1 trial for its vaccine candidate and is reporting optimistic results, making shares jump last week.

Japanese biotech company, Takara Bio Inc is also commencing trials with production facilities ready. Takara partnered with bio company AnGes and Osaka University to develop the DNA COVID-19 vaccine.

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

Related Articles

Worldwide

Post Views: 86 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. About 90 per...

Politics

Post Views: 20 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Obama rips Trump,...

Fashion

Post Views: 24 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Hear from Carla...

Worldwide

Post Views: 37 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Jon Gwyther shot...

Advertisement
Advertisement
Advertisement
Advertisement